Research programme: ImmunoVEX vaccines - Sanofi-Aventis
Alternative Names: ImmunoVEX vaccines research programme - Sanofi-AventisLatest Information Update: 18 Mar 2009
At a glance
- Originator sanofi-aventis
- Class Vaccines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 May 2006 Discontinued - Preclinical for Undefined indication in France (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 22 Jun 2001 Preclinical development for Undefined in France (Unknown route)